Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Organovo Holdings (ONVO)

Organovo Holdings (ONVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 47,609
  • Shares Outstanding, K 130,435
  • Annual Sales, $ 3,090 K
  • Annual Income, $ -26,640 K
  • 60-Month Beta 2.18
  • Price/Sales 14.73
  • Price/Cash Flow N/A
  • Price/Book 1.46
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.22
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/06/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.34 +7.04%
on 01/23/20
0.51 -28.43%
on 01/09/20
-0.05 (-13.07%)
since 12/24/19
3-Month
0.25 +43.14%
on 10/25/19
0.65 -43.85%
on 12/16/19
+0.10 (+35.74%)
since 10/24/19
52-Week
0.22 +66.21%
on 08/07/19
1.18 -69.07%
on 02/25/19
-0.64 (-63.86%)
since 01/24/19

Most Recent Stories

More News
The Case Against Tarveda: An Open Letter to Organovo Shareholders

Organovo Founder Keith Murphy sent the following letter to company shareholders:

ONVO : 0.37 (+4.58%)
An Open Letter to Organovo Shareholders: Organovo Founder Sees Continued Success in Bioprinting

Organovo Founder Keith Murphy sent the following letter to company shareholders:

ONVO : 0.37 (+4.58%)
Organovo and Tarveda Therapeutics Announce Definitive Merger Agreement

--Transaction to advance Tarveda's proprietary Pentarin(R) miniature drug conjugates including its two clinical programs for the treatment of solid tumor malignancies

ONVO : 0.37 (+4.58%)
Will Organovo Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Organovo.

ONVO : 0.37 (+4.58%)
Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys

Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys

QLYS : 86.75 (-0.30%)
CYBR : 140.41 (+0.19%)
AVGR : 1.00 (-6.54%)
ONVO : 0.37 (+4.58%)
ALXN : 105.27 (-3.02%)
What Bargain Hunting? Tap 5 Stocks With Rising P/E

Bet on these top-ranked stocks with rising P/E for outsized gains.

QLYS : 86.75 (-0.30%)
CYBR : 140.41 (+0.19%)
AVGR : 1.00 (-6.54%)
ALXN : 105.27 (-3.02%)
ONVO : 0.37 (+4.58%)
Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ONVO : 0.37 (+4.58%)
Organovo Acknowledges Receipt of Proposal

Organovo Holdings, Inc. (NASDAQ: ONVO) ("Organovo") today confirmed that it has received a proposal from Viscient Biosciences ("Viscient"), an early-stage private company headquartered in San Diego, California,...

ONVO : 0.37 (+4.58%)
Viscient Biosciences Proposes Merger to Unlock 3D Bioprinting Potential in Drug Discovery With Organovo

Viscient Biosciences ("Viscient"), a biotech therapeutics company working at the intersection of 3D tissue technology and transcriptomics technology to discover and develop drugs across a range of therapeutic...

ONVO : 0.37 (+4.58%)
Viscient Biosciences Proposes Merger to Unlock 3d Bioprinting Potential in Drug Discovery with Organovo

Combined Entity will Enable Significant Developments in High-Value Indications Beyond NASH Blockbuster Opportunity

ONVO : 0.37 (+4.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade ONVO with:

Business Summary

Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings,...

See More

Key Turning Points

2nd Resistance Point 0.39
1st Resistance Point 0.38
Last Price 0.37
1st Support Level 0.35
2nd Support Level 0.34

See More

52-Week High 1.18
Fibonacci 61.8% 0.81
Fibonacci 50% 0.70
Fibonacci 38.2% 0.59
Last Price 0.37
52-Week Low 0.22

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar